Concepedia

Nicolas Guérard

NG

6

Publications

332

Citations

6

H-Index

2008

Active since

Affiliations

Actelion (Switzerland)(Current)

Novartis (Switzerland)

Idorsia (Switzerland)

Nicolas Guérard is an author at Actelion (Switzerland) specializing in medicine, drug safety, and drug discovery.

Top concepts

MedicineCardiologyPhysiologyToxicologyDrug SafetyCell BiologyGlycobiologyPharmacologyHeart FailureCell Signaling

Publications per year

2008–2024

6

Publications

6

Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy

Vlado Perkovic, Jonathan Barratt, Brad H. Rovin et al. · New England Journal of Medicine · 2024 · 117 citations

Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement

Nicolas Guérard, Daniel Oder, Peter Nordbeck et al. · Clinical Pharmacology & Therapeutics · 2017 · 106 citations

Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects

Nicolas Guérard, O. Morand, Jasper Dingemanse · Orphanet Journal of Rare Diseases · 2017 · 40 citations · Full text

Drug Safety, Fabry Disease, Mg Lucerastat +15

Selective block of IKs plays a significant role in MAP triangulation induced by IKr block in isolated rabbit heart

Nicolas Guérard, Martin Traebert, Willi Suter et al. · Journal of Pharmacological and Toxicological Methods · 2008 · 29 citations

Mechanobiology, Cardiac Muscle, Cardiomyopathy +13

Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet

Pierre Gueneau de Mussy, Patricia N. Sidharta, Grégoire Wuerzner et al. · Clinical Pharmacology & Therapeutics · 2020 · 26 citations · Full text

Rows per page

1–5 of 6